BioLizard
BioLizard is a Belgium-based bioinformatics and AI services firm that pairs its proprietary Bio|Verse analytics platform with expert scientific consulting to help pharma, biotech, diagnostic, and academic clients turn multi-omics and biomedical data into R&D decisions across discovery through post-marketing.
- Company typePrivate
- Founded2019
- HeadquartersGhent, Belgium
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What BioLizard does
BioLizard is a privately held bioinformatics and AI services company founded in 2019 and headquartered in Ghent, Belgium, with wholly-owned subsidiaries in the United States (Chicago), the Netherlands (Amsterdam), and Switzerland (Epalinges, established January 2024). The company employs 51-100 domain experts spanning biology, bioinformatics, data science, and software engineering and operates a tech-enabled services model that pairs proprietary software with hands-on scientific consulting.
Its core offering is the Bio|Verse modular analytics platform, which combines a data orchestration layer, FAIR-compliant infrastructure, and a set of specialized applications: Bio|Verse Navigator (visual analytics workspace), Bio|Mx (AI-driven multi-omics integration), Bio|Reflect (LLM-assisted literature exploration), and Pro|Biome (microbiome analytics). BioLizard works across multi-omics modalities (genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial) and applies techniques including graph convolutional neural networks, large language models, computer vision for spatial biology, and Digital Twin Cell simulation.
Revenue is generated through professional services engagements, recurring platform licensing for Bio|Verse modules, and custom analytics applications, sold via a direct enterprise motion supported by industry events (JPM Week, Biotech Showcase, Swiss Biotech Day). Pricing is quote-based and not publicly disclosed. The customer base spans pharmaceutical and biotech companies, diagnostic developers, academic institutions, and government health agencies, with named outcomes including a $250M Novartis acquisition supported by BioLizard multi-omics and single-cell analysis, alongside engagements with Pierre Fabre Group and the New York State Department of Health. BioLizard has no publicly disclosed funding rounds but has received non-dilutive support through a VLAIO grant for LLM-powered platform extensions.
BioLizard firmographics
Firmographics- Name
- BioLizard
- Legal name
- BioLizard nv
- Website
- https://lizard.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioLizard is a Belgium-based bioinformatics and AI services firm that pairs its proprietary Bio|Verse analytics platform with expert scientific consulting to help pharma, biotech, diagnostic, and academic clients turn multi-omics and biomedical data into R&D decisions across discovery through post-marketing.
- Ownership category
- akta.pro rank
BioLizard industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industries
- Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where BioLizard is headquartered
LocationHeadquarters
- HQ city
- Ghent
- HQ country
- Belgium
- HQ region
- Europe
Offices4 records
Markets served
BioLizard business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Tech-Enabled Services: Consulting and professional services model combining advanced technology with hands-on scientific and data expertise. Delivers high-impact, end-to-end solutions with expert collaboration and biology-driven thinking.
- Software Platform Licensing: Bio|Verse platform with optional applications that support common R&D needs such as exploring biological mechanisms, identifying biomarkers, or comparing results across studies. Organizations can add capabilities without building new tools.
- Custom Analytics Applications: Tailored software solutions fully customized to client needs, enabling data-driven discovery, preclinical, translational and clinical R&D processes.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
BioLizard product offering
Product offeringCore offering
BioLizard provides a tech-enabled services model centered on its proprietary Bio|Verse® modular analytics platform, which combines a data orchestration layer, the Bio|Verse® Navigator visual analytics workspace, and modular AI applications (Bio|Mx®, Bio|Reflect®, Pro|Biome™) for life sciences R&D. The platform is paired with hands-on expert scientific and data consultation, where biologists, data scientists, and engineers work directly with client teams across drug discovery, translational research, clinical development, and diagnostics. The offering is delivered to biotech, pharmaceutical, diagnostic, and academic organizations globally.
Product overview
BioLizard offers the Bio|Verse® modular analytics platform for life sciences R&D, which includes multiple specialized applications: Bio|Verse® Navigator (visual analytics workspace), Bio|Mx® (AI-driven multi-omics integration), Bio|Reflect® (publication exploration), and Pro|Biome™ (microbiome analysis). The platform is complemented by a tech-enabled services model combining software with expert scientific consultation. The ecosystem supports organizations from small biotech to leading pharmaceutical companies across drug discovery, translational research, clinical development, and diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- Bio|Verse: A modular analytics platform enabling intuitive exploration, custom workflows, and scalable infrastructure for life sciences organizations. Includes Navigator visual analytics workspace, Bio|Reflect, Pro|Biome, and Bio|Mx applications.
- Bio|Verse Navigator
- Bio|Reflect
- Pro|Biome
- Bio|Mx
Products and services
- Bio|Verse® Core modular analytics platform providing data orchestration, visual analytics, and FAIR-compliant infrastructure for life sciences R&D. Enables intuitive exploration, custom workflows, and scalable infrastructure built around client science, combining advanced software, reusable analytics applications, and biological expertise.
- Bio|Verse® Navigator Visual analytics workspace that unifies complex R&D data allowing scientists to explore and interpret biomedical data in real time. Built on Bio|Verse®'s data orchestration layer, it enables faster, more confident decision-making.
- Bio|Mx® AI-driven multi-omics integration and analysis application that combines genomics, transcriptomics, proteomics, metabolomics, and epigenomics data through machine learning (including graph convolutional neural networks) and biological expertise to facilitate biomarker and target discovery.
- Bio|Reflect® Publication exploration application providing at-a-glance and up-to-date global overviews of scientific literature to support unbiased literature searches for life sciences R&D teams.
- Pro|Biome™ Microbiome analysis application applying state-of-the-art data analytics to microbiome research for human health, animal health, and agriculture applications.
- Tech-Enabled Services Hybrid service model combining advanced Bio|Verse® technology with hands-on scientific and data consultation. Expert biologists, data scientists, and engineers work directly with client teams to deliver tailored analytics and AI solutions across drug discovery, translational research, clinical development, and diagnostics.
Quantifiable outcome
- Reduced manual analysis from days to minutes through in-silico antibody mining
- +2 more outcomes
Companies that use BioLizard
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
BioLizard technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature7 records
BioLizard partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- AbnomXcoreStrategic partnership to accelerate antibody discovery. Combines BioLizard's advanced analytics with AbnomX's Antibody-Extractor platform, enabling scientists to transform immune repertoire data into actionable insights.
- BioWinminorBioLizard joined BioWin, Wallonia's leading health cluster, to collaborate with innovators in biotech, medtech, and research. Partnership strengthens mission to leverage data for better health outcomes and accelerate life sciences innovation in the region.
- Parean BiotechnologiescorePartnership to advance immune omics insights. Parean's cutting-edge immune system decoding complements BioLizard's AI-driven analytics, enabling deeper insights from complex immunological datasets to drive R&D forward.
- Da's Geniaal ConsortiumminorJoined Da's Geniaal consortium supporting its mission to inspire 10-14-year-olds, especially girls, to explore science and technology. Aligns with BioLizard's commitment to sustainability, diversity, equity, and inclusion.
- Pistoia AllianceminorBioLizard joined the Pistoia Alliance, a global life sciences network fostering pre-competitive collaboration to accelerate R&D. Contributes to innovative, data-driven solutions alongside 200+ member organizations worldwide.
- Bits in Bio BelgiumminorBioLizard hosted Bits in Bio Belgium meeting, bringing together 50+ attendees to explore AI and machine learning in life sciences. Talks highlighted data governance, pipeline optimization, and interactive ML tools, fostering networking and collaboration.
- Scaler8minorPartnership with Scaler8's Explore Programme to unlock novel US market opportunities. Leverages Scaler8's expertise and network to expand into the US market and bring advanced computational and predictive biological modeling to US clients.
- TercencorePartnership combining BioLizard's advanced bioinformatics and AI/ML services with Tercen's intuitive low-code analytics platform, enabling faster, more comprehensive biomedical data analysis and visualization for life sciences researchers worldwide.
- Bridge InformaticsminorInterview and partnership between BioLizard and Bridge Informatics CEOs discussing opportunities, challenges, and areas for growth at the intersection of biology and data science.
- Vlerick Business SchoolminorOngoing relationship with Vlerick Business School including awards recognition for leadership and entrepreneurship, connecting academic excellence with industry practice.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
BioLizard competitors and assessment
Company assessmentEmerging players
- TetraScience: Builds an R&D data cloud and AI-data lake for life sciences, addressing the same data orchestration and FAIR-compliance pain points that BioLizard's Bio|Verse targets.
- Schrödinger: Applies computational physics and AI to molecular discovery and translational research; a publicly listed peer operating at the intersection of AI, multi-omics and drug discovery that competes for similar enterprise wallet share.
- Recursion: AI-driven drug discovery platform integrating high-throughput biology with machine learning, competing for pharma AI/translational R&D budgets where BioLizard also pitches its AI/ML multi-omics capabilities.
- Insitro: Combines machine learning with high-throughput biology for target discovery and patient stratification—comparable in offering AI-driven, biology-grounded R&D services to pharma partners.
Direct peers
- DNAnexus: Provides a cloud-based genomics and multi-omics data management and analysis platform, closely paralleling BioLizard's Bio|Verse data orchestration and analytics capabilities for pharma/biotech R&D.
- Seven Bridges: Offers a bioinformatics platform plus expert analytical services for genomics and multi-omics, mirroring BioLizard's hybrid software-plus-tech-enabled services model targeting pharma and academic R&D.
- Eagle Genomics: Delivers an AI-enabled multi-omics analytics platform for microbiome and life sciences R&D customers, directly overlapping BioLizard's Bio|Mx and Pro|Biome product lines.
- Genedata: Provides enterprise scientific informatics software (Screener, Expressionist, Selector) to biopharma R&D, competing for the same pharmaceutical bioinformatics budget as BioLizard's Bio|Verse.
- Dotmatics: Offers a unified scientific R&D platform (e.g., GraphPad, SnapGene, LabLogic) for life sciences discovery workflows; a direct adjacent competitor for BioLizard's FAIR-compliant R&D data infrastructure.
Broad incumbents
- Benchling: Provides a broad R&D cloud platform spanning ELN, LIMS, and bioregistry, with growing investment in AI/analytics—larger incumbent competing for BioLizard's biotech and pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioLizard social profiles
Digital presenceBioLizard financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLizard leadership team
Management profileNumber of profiles
Profiles8 records
BioLizard subsidiaries and ownership
Company hierarchySubsidiaries3 records
BioLizard funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLizard M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLizard
What does BioLizard do?
BioLizard provides a tech-enabled services model centered on its proprietary Bio|Verse® modular analytics platform, which combines a data orchestration layer, the Bio|Verse® Navigator visual analytics workspace, and modular AI applications (Bio|Mx®, Bio|Reflect®, Pro|Biome™) for life sciences R&D. The platform is paired with hands-on expert scientific and data consultation, where biologists, data scientists, and engineers work directly with client teams across drug discovery, translational research, clinical development, and diagnostics. The offering is delivered to biotech, pharmaceutical, diagnostic, and academic organizations globally.
Is BioLizard a public or private company?
BioLizard is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioLizard founded?
BioLizard was founded in 2019. It employs 51 to 100 people.
Where is BioLizard based?
BioLizard is headquartered in Ghent, Belgium, in the Europe region.
How does BioLizard make money?
Three revenue lines are on record. Tech-Enabled Services are the primary driver. The others are software Platform Licensing and custom Analytics Applications.
Who are BioLizard's main competitors?
Emerging players on record are TetraScience, Schrödinger, Recursion and Insitro. Direct peers are DNAnexus, Seven Bridges, Eagle Genomics, Genedata and Dotmatics. Benchling is listed as a broad incumbent.
Does BioLizard have an API?
No public API is recorded for BioLizard.
What industry is BioLizard in?
BioLizard's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAN, Knowledge Management & Scientific Collaboration / Literature Intelligence. Its NAICS code is 541714 and its SIC code is 8731.